The Pox-Protein Public Private Partnership (P5) – comprised of the Bill & Melinda Gates Foundation, the National Institutes of Health, Sanofi Pasteur, GlaxoSmithKline (GSK), the South African Medical Research Council, the HIV Vaccine Trials Network (HVTN), and the US Military HIV Research Program – is a diverse group of organizations committed to building upon the modest protective efficacy observed in the RV144 trial. If efficacious, a preventive vaccine could substantially impact the epidemic and improve public health by reducing the incidence of new infections globally.
- Dr. Mary Marovich, Director, Vaccine Research Program
- Dr. Dale Hu, Chief, Vaccine Clinical Research Branch
Main Areas of Focus
- The modest protective efficacy observed in the RV144 trial led to the identification of the V2 antibody correlate hypothesis and the development of the P5
- The P5 program aims to improve upon the RV144 efficacy result and test the V2 hypothesis using vaccine constructs adapted for the subtype C epidemic in RSA
An early-stage HIV vaccine clinical trial in South Africa called HVTN 100 has determined that an investigational vaccine regimen is safe and generates comparable immune responses to those reported in a landmark 2009 study showing that a vaccine can protect people from HIV infection. Consequently, NIAID and its partners decided to advance the experimental HIV vaccine regimen into a large clinical trial known as HVTN 702. This study is designed to determine whether the regimen is safe, tolerable and effective at preventing HIV infection among South African adults. The trial, which began in late 2016, is currently ongoing.